Skip to main content
Premium Trial:

Request an Annual Quote

NSF Grants Cornell $5.5M for Genome Editing in Rice

NEW YORK (GenomeWeb) — Cornell University announced this week that scientists led by Adam Bogdanove have received a $5.5 million grant from the National Science Foundation for a gene editing project in rice.

The four-year grant will try to provide proof of concept that genome editing can be used to address important measurable agricultural traits in rice, including plant height, yield, disease resistance, and soil acidity tolerance. The scientists will develop a genome editing platform for crop breeding as well as new lines of rice expressing the improved traits.

Bogdanove said that the scientists have already identified particular stretches of DNA as candidates for the quantitative traits of interest.

The project will use data released in 2014 from an international project that sequenced 3,000 different rice genomes from around the world.

The grant did not mention the use of any particular genome editing technologies. Bogdanove is co-creator of transcription activator-like effector nucleases (TALENs); Daniel Voytas, a professor at the University of Minnesota, chief scientific officer at Cellectis Plant Sciences and co-developer of TALENs, is also listed as a co- investigator on the grant. Rice genetics researcher Susan McCouch is also a co-investigator and a professor at Cornell.

In 2011, the NSF awarded researchers at Cornell and the University of California, Riverside $4.8 million to study transposable elements in the rice genome.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.